Ocular implants and inserts: revolutionizing drug delivery in ophthalmology

Area of Science:

• Ophthalmology and Drug Delivery Systems
• Biomaterials and Nanotechnology in Ocular Therapeutics
• Medical Device Engineering for Ophthalmic Applications

Background:

• Ophthalmic drug delivery is limited by ocular barriers, resulting in poor bioavailability (<5%) and frequent dosing.
• Conventional methods like eye drops and ointments have drawbacks including reflex blinking and tear turnover.
• There is a critical need for sophisticated drug delivery systems for sustained and site-specific ocular drug delivery.

Purpose of the Study:

• To provide a comprehensive analysis of implantable and insertable ocular drug delivery technologies.
• To examine the mechanisms, applications, innovations, and design considerations of various ocular devices.
• To highlight clinical applications, regulatory aspects, and future directions in ocular therapeutics.

Main Methods:

• Review of existing literature on ocular implants and inserts.
• Analysis of various device categories: Intacs rings, ocular ring inserts, drug-eluting contact lenses, intracameral implants, conjunctival inserts, intraocular lenses/inlays, micro/nanoparticles, intravitreal implants, and microneedles.
• Examination of working mechanisms, clinical applications, technological innovations, and design considerations for each device type.

Main Results:

• The global ocular implant market is substantial and growing, driven by demand for minimally invasive, long-acting treatments.
• Diverse implantable and insertable technologies exist, including those for drug delivery and refractive error correction.
• Advancements in AI, IoT, smart materials, and 3D printing are enhancing ocular care diagnostics and management.

Conclusions:

• Implantable and insertable devices are crucial for overcoming ocular drug delivery limitations, offering controlled and site-specific therapeutic effects.
• Technological innovations are rapidly advancing the potential of these devices for treating a wide range of ocular conditions.
• Addressing research gaps and regulatory challenges is essential for translating these advancements into widespread clinical practice.